Lung Neuroendocrine Tumours

Lung neuroendocrine tumours (NETS), also known as bronchopulmonary NETS, pulmonary NETs or lung carcinoid tumours, are a group of neuroendocrine tumours that develop in within the lungs, which are the primary organs of our respiratory system and allow us to breathe. The lungs are a pair of cone-shaped organs that are located under our ribcage.

The respiratory system is composed of the nose, mouth, trachea (windpipe) and airways (bronchi and bronchioles) that lead to the lungs, which is where the breathing process primarily occurs. Each lung is made up of lobes, with the right lung being composed of three lobes and the left only having two lobes to accommodate room for the heart. The lungs sit on top of a muscle called the diaphragm, which separates the abdomen from the chest. The diaphragm works by contracting/flattening when we inhale, pulling air into the lungs. When we exhale, the diaphragm relaxes and pushes air out of the lungs. The space between the lungs is called the mediastinum, and holds several important structures, including the heart, trachea, oesophagus and lymph nodes. Each lung is covered by a layer of tissue called the pleura.

Neuroendocrine cancers are a complex group of tumours that develop in the neuroendocrine system, which is responsible for regulating important bodily functions such as heart rate, blood pressure and metabolism. They most commonly develop in the gastro-intestinal tract, pancreas, and the lungs; however, they can develop anywhere in the body. These tumours develop from neuroendocrine cells, which are responsible for receiving signals from the nervous system and producing hormones and peptides (small proteins) in response.

Lung NETs are slightly more common in males, and tend to be diagnosed between the ages of 40-60. However, anyone can develop this disease.

Types of Lung NETs

There are four primary types of lung NETs, including typical carcinoid lung NETS, atypical lung NETS, small cell carcinoma and large cell neuroendocrine carcinoma. Lung NETs are categorised based on cell type and tumour behaviour.

Carcinoid Lung NETs

Typical Lung NETs

Typical carcinoid lung NETs are the most common form of lung NETs, and rarely spread beyond the lungs. They have not been linked to smoking, are generally slow growing, and can have a good prognosis when caught early.

Atypical Carcinoid Lung NETs

Atypical carcinoid lung NETs are a less common form of lung NET that can be more aggressive than typical carcinoid lung NETs. They have also not been linked to smoking, however they have a higher risk of metastasis than typical carcinoid lung NETs. Atypical carcinoid lung NETs can have a good prognosis when found early.

Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH)

Diffuse intrapulmonary neuroendocrine cell hyperplasia (DIPNECH) is a rare and poorly understood condition that occurs when neuroendocrine cells of the lungs start to grow uncontrollably. It is thought to be a precursor to the development of typical and atypical carcinoid lung NETs.

Small Cell Carcinoma

Small cell lung cancer (SCLC), or oat cell carcinoma, is the less common type of lung NET that generally starts in the bronchi of the lungs. SCLC has been linked to smoking, are generally diagnosed at a later stage of disease, and may not have as good of a prognosis as other types of lung NETs.

Large Cell Neuroendocrine Carcinoma

Large cell neuroendocrine carcinomas are the rarest form of lung NET that generally originates from the bronchi of the lungs. It has features of both small cell lung cancer and non-small cell lung cancer, and has been linked to smoking. Large cell neuroendocrine carcinomas can be aggressive, are likely to metastasise, and may not have as good of a prognosis as other types of lung NETs.

Treatment

If a lung NET is detected, it will be staged and graded based on size, metastasis, and how the cancer cells look under the microscope. Staging and grading helps your doctors determine the best treatment for you.

Cancers can be staged using the TNM staging system:

  • T (tumour) indicates the size and depth of the tumour.
  • N (node) indicates whether the cancer has spread to nearby lymph nodes.
  • M (metastasis) indicates whether the cancer has spread to other parts of the body.

This system can also be used in combination with a numerical value, from stage 0-IV:

  • Stage 0: this stage describes cancer cells in the place of origin (or ‘in situ’) that have not spread to nearby tissue.
  • Stage I: cancer cells have begun to spread to nearby tissue. It is not deeply embedded into nearby tissue and had not spread to lymph nodes. This stage is also known as early-stage cancer.
  • Stage II: cancer cells have grown deeper into nearby tissue. Lymph nodes may or may not be affected. This is also known as localised cancer.
  • Stage III: the cancer has become larger and has grown deeper into nearby tissue. Lymph nodes are generally affected at this stage. This is also known as localised cancer.
  • Stage IV: the cancer has spread to other tissues and organs in the body. This is also known as advanced or metastatic cancer.

Cancers can also be graded based on the rate of growth and how likely they are to spread:

  • Grade I: cancer cells present as slightly abnormal and are usually slow growing. This is also known as a low-grade tumour.
  • Grade II: cancer cells present as abnormal and grow faster than grade-I tumours. This is also known as an intermediate-grade tumour.
  • Grade III: cancer cells present as very abnormal and grow quickly. This is also known as a high-grade tumour.

Once your tumour has been staged and graded, your doctor may recommend genetic testing, which analyses your tumour DNA and can help determine which treatment has the greatest chance of success. This is often performed after a biopsy, and can help guide treatment options for you.

Treatment is dependent on several factors, including location, stage of disease and overall health.

Treatment options for lung NETs may include:

  • Surgery to remove as much of the tumour(s) as possible.
  • Chemotherapy.
  • Radiation therapy.
  • Targeted therapy.
  • Hormone therapy, potentially including somatostatin analogues.
  • Immunotherapy.
  • Cryotherapy.
  • Watch and wait (for early stage and slow-growing cancers).
  • Clinical trials.
  • Palliative care.

Risk factors

While the cause of lung NETs remains unknown, some of the following factors may increase the risk of disease.

  • Genetic syndromes, such as multiple endocrine neoplasia syndrome type 1 (MENS1).
  • History of smoking.

Not everyone with these risk factors will develop the disease, and some people who have the disease may have none of these risk factors. See your general practitioner (GP) if you are concerned.

Symptoms

Some patients with lung NETs will appear asymptomatic in the early stages of disease. As the tumour progresses, some of the following symptoms may appear.

  • Carcinoid syndrome, which carries its own set of symptoms:
    • Facial flushing (usually red or purple in the face, neck, and/or upper chest).
    • Diarrhoea.
    • Wheezing.
    • Abdominal pain.
    • Carcinoid heart disease (plaques on the heart muscle caused by excess hormone production).
    • Faecal urgency.
    • Fatigue.
    • Skin changes, such as red or purple spots on the face, neck, and/or upper chest.
  • Persistent cough.
  • Wheezing.
  • Breathlessness or difficulties breathing.
  • Chest pain.
  • Coughing or spitting up blood.
  • Persistent chest infections.
  • Fatigue.
  • General weakness.
  • Unexplained weight loss/loss of appetite.

Not everyone with the symptoms above will have cancer, but see your general practitioner (GP) if you are concerned.

Diagnosis

If your doctor suspects you have a lung NET, they may order the following tests to confirm the diagnosis and refer you to a specialist for treatment:

  • Physical examination.
  • Imaging tests, potentially including:
    • Chest X-ray.
    • MRI (magnetic resonance imaging).
    • CT (computed tomography) scan.
    • PET (positron emission tomography) scan.
  • Blood tests.
  • Bronchoscopy.
  • Biopsy.

References

Related Support Services

See More arrow_forward

Keep up with Rare Cancers Australia

Inside Rare is a monthly newsletter that shares the latest news, events and stories connecting the rare community.